As of Wednesday close, PharmaCyte Biotech Inc.’s (NASDAQ:PMCB) stock was up $0.07, moving up 2.33 percent to $3.07. The average number of shares traded per day over the past five days has been 64,020 shares. 4 times new highs have been achieved over the past 5 days, with a $0.14 gain in that time frame. In the last twenty days, the average volume was 65,040, while in the previous 50 days, it was 103,670.
Since last month, PMCB stock rose 4.78%. Shares of the company fell to $2.78 on 11/03/22, the lowest level in the past month. A 52-week high of $3.10 was reached on 11/15/22 after having rallying from a 52-week low of $1.79. Since the beginning of this year, PMCB’s stock price has risen by 22.80% or $0.57, and marked a new high 12 times. However, the stock has declined by -0.97% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
In the three months ended July 30, PharmaCyte Biotech Inc.’s quick ratio stood at 75.50, while its current ratio was 75.50, showing that the company is able to pay off its debt. Based on annual data, PMCB earned $1000.0 in gross profit and brought in $4.39 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected PharmaCyte Biotech Inc. to report -$0.07 quarterly earnings, the actual figure was -$0.07 per share. During the quarter, the company generated -$1.68 million in EBITDA. The liabilities of PharmaCyte Biotech Inc. were 1.09 million at the end of its most recent quarter ended July 30, and its total debt was $3340.0. The value of shareholders’ equity is $20.75 million.
This quick technical analysis looks at PharmaCyte Biotech Inc.’s (PMCB) price momentum. With a historical volatility rate of 23.67%, the RSI 9-day stood at 70.62% on 23 November.
With respect to its five-day moving average, the current PharmaCyte Biotech Inc. price is up by +4.78% percent or $0.14. At present, PMCB shares trade +3.72% above its 20-day simple moving average and +33.48% percent above its 100-day simple moving average. However, the stock is currently trading approximately +18.53% above its SMA50 and +43.46% above its SMA200.
Stochastic coefficient K was 67.50% and Stochastic coefficient D was 54.10%, while ATR was 0.12. Given the Stochastic reading of 90.00% for the 14-day period, the RSI (14) reading has been calculated as 67.25%. As of today, the MACD Oscillator reading stands at 0.03, while the 14-day reading stands at 0.04.
PharmaCyte Biotech Inc. (PMCB) has been rated Hold by analysts. According to 0 brokerage firms, PMCB is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate PharmaCyte Biotech Inc. stock as buy, with 0 recommending it as overweight.